🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Agilent And Burning Rock Team Up For Cancer Diagnostics

Published 10/02/2016, 10:12 PM
Updated 07/09/2023, 06:31 AM
A
-
LNKD
-
AUTO
-
YRD
-

Agilent Technologies, Inc.’s (NYSE:A) business has seen significant growth in China and the company continues to boost its presence in this market with its leading Life Science Tools.

The company has sealed a partnership with Burning Rock per which the latter will use Agilent SureSelect target enrichment system to develop cancer diagnostics in China.

Taking Cancer Diagnostics a Step Ahead in China

Through this partnership, the duo will be able to offer high-quality molecular diagnostic solutions including relapse monitoring, non-invasive testing, early-stage diagnosis and cancer susceptibility.

Agilent’s target enrichment system increases research accuracy and significantly saves time and resources by concentrating on regions of interest rather than the entire genome.

President of Agilent’s Diagnostics and Genomics Group Jacob Thaysen stated that “We believe that target enrichment and next-generation sequencing have a vital role to play in personalizing medicine and ultimately delivering treatments tailored to the individual. This is especially so for complex diseases such as cancer.”

The partnership makes sense for both the companies because China’s large population and increasing health awareness calls for quick and accurate cancer diagnosis.

AGILENT TECH Price

Agilent’s China Growth Story

China is emerging as a major driver of Agilent’s business, mainly because of its position as a manufacturing destination. Agilent makes test equipment that is required by manufacturers. The company’s strong market position and customer relationships in China are long-term drivers of its business. Chinese stimulus plans have fueled growth in the past and the laws passed by the government regarding food safety and environmental testing offer additional growth opportunity for Agilent.

In addition, the strength in the Life Science Tools (LST) market is expected to come from increased innovation, usage of high-end technologies in new applications and an expanded customer base. The emergence of cell-based technologies and clinical diagnostics further increase opportunities for Agilent.

About the Duo

Agilent, spun off from Hewlett-Packard in 2000, is a global leader in life sciences communications, electronics, communications and chemical analysis. Agilent has two primary business segments: Bio-Analytical Measurement and Electronic Measurement that operate in close collaboration with scientists, engineers and researchers from across the globe.

Burning Rock is a China-based diagnostic company engaged in developing cancer diagnostics based on DNA sequencing.

Zacks Rank and Stocks to Consider

Currently, Agilent is a Zacks Rank #3 (Hold) stock. Better-ranked stocks in the in the broader technology sector include LinkedIn Corporation (NYSE:LNKD) , Autobytel Inc. (NASDAQ:ABTL) and Yirendai Ltd. (NYSE:YRD) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Linkedin has seen estimates for the full year rise over the past 60 days by more than 100%. For Autobytel, estimates rose 11.2% in the last 60 days. Over the same period, Yirendai saw its estimates go up by 33.6%.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



AUTOBYTEL INC (ABTL): Free Stock Analysis Report

AGILENT TECH (A): Free Stock Analysis Report

LINKEDIN CORP-A (LNKD): Free Stock Analysis Report

YIRENDAI LTD (YRD): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.